The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Abstract
A locus segregating with familial Alzheimer's disease (AD) has been mapped to chromosome 21, close to the amyloid precursor protein (APP) gene. Recombinants between the APP gene and the AD locus have been reported which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous. Families with late-onset AD do not show linkage to chromosome 21 markers. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD. To avoid the problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val----Ile) close to the carboxy terminus of the beta-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FAD mutations in APP that cluster near the 𝛃 - and 𝛄 -secretase cleavage sites either elevate the production of total A 𝛃 , as is the case with the K670N/ M671L substitution [Swedish mutation (Mullan et al., 1992a)], or increase the generation of A 𝛃 42 specifically, as occurs with the I716V [Florida mutation (Eckman et al., 1997)] and V717I [London mutation (Goate et al., 1991)] substitutions.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Goate et al., 1991
In the citing paper
“The 5XFAD mouse, along with the APPSLPS1KI, is one of a few known mouse models that exhibits significant neuron loss in addition to displaying other AD hallmarks such as amyloid plaques [10,11,16].”
From Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation (2013) · cites this paper as [10]
In the citing paper
“Frank neuron loss has been observed in two aggressive amyloid plaque transgenic mouse models that also exhibit accumulation of intraneuronal Aβ42 prior to plaque formation: the 5XFAD and APPSLPS1K1 lines [10,11].”
From Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation (2013) · cites this paper as [10]
In the citing paper
“Early onset Alzheimer's disease can be caused by mutations in the APP (Chartier-Harlin et al., 1991;Goate et al., 1991;Murrell et al., 1991;Mullan et al., 1992), presenilin 1 (PS1) (Sherrington et al., 1995), and presenilin 2 (PS2) (Levy-Lahad et al., 1995) genes.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Goate et al., 1991
In the citing paper
“The amyloid cascade hypothesis of Alzheimer disease (AD), which proposes that deposition of the amyloid-β (Aβ) peptide in the brain is a central event in disease pathology (Figure 1), is strongly supported by neuropathological and human genetic evidence”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [2]
In the citing paper
“Mutations in APP, presenilin 1 (PSEN1) and PSEN2 genes that increase Aβ production, elevate Aβ42/Aβ40 ratio and promote plaque formation cause autosomal dominant early-onset familial AD (FAD)”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [38]
In the citing paper
“Less than 1% of all AD cases are early-onset with symptoms developed at an age of 50 s and earlier, and caused by gene mutations in APP, PSEN1 or PSEN2.7,38,39”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [38]
In the citing paper
“This hypothesis gained favor in the 1990s after several gene mutations directly responsible for aberrant Aβ accumulation (APP, PSEN1, PSEN2) were found to underlie rare familial forms of early-onset AD [20–22].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [21]
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Garnier, J., Osguthorpe, D. J., & Robson, B. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90297-8 · Cited by 4,523
Strategies for multilocus linkage analysis in humans.
Lathrop, M. G., Lalouel, J.-M., Julier, C., & Ott, J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3443 · Cited by 2,560
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I. M., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,399
Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987) · Science · doi:10.1126/science.3810169 · Cited by 1,359
The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
George‐Hyslop, P. S., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L. E., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D. A., Drachman, D. A., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,160
Hydrophobic cluster analysis: An efficient new way to compare and analyse amino acid sequences
Gaboriaud, C., Bissery, V., Benchetrit, T., & Mornon, J. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80439-8 · Cited by 618
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,066
Huitrón‐Reséndiz, S., Sánchez-Alavez, M., Gallegos, R. A., Berg, G. I., Crawford, E. F., Giacchino, J. L., Games, D., Henriksen, S. J., & Criado, J. R. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03373-x · Cited by 122
A Novel Presenilin‐2 Splice Variant in Human Alzheimer's Disease Brain Tissue
Sato, N., Hori, O., Yamaguchi, A., Lambert, J., Chartier‐Harlin, M., Robinson, P. A., Delacourte, A., Schmidt, A. M., Furuyama, T., Imaizumi, K., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722498.x · Cited by 122
Self-citationTherapeutic role of sirtuins in neurodegenerative disease
Outeiro, T. F., Marques, O., & Kazantsev, A. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.02.010 · Cited by 122
Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats
Itoh, A., Akaike, T., Sokabe, M., Nitta, A., Iida, R., Olariu, A., Yamada, K., & Nabeshima, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00601-9 · Cited by 122
Generation and Regulation of β‐Amyloid Peptide Variants by Neurons
Gouras, G. K., Xu, H., Jovanovic, J. N., Buxbaum, J. D., Wang, R., Greengard, P., Relkin, N. R., & Gandy, S. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71051920.x · Cited by 122
Early-infantile galactosialidosis: Prenatal presentation and postnatal follow-up
Patel, M. S., Callahan, J. W., Zhang, S., Chan, A. K. J., Unger, S., Levin, A. V., Skomorowski, M., Feigenbaum, A. S. J., O’Brien, K., Hellmann, J., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990702)85:1 · Cited by 45
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder
Lesch, K., Gross, J., Franzek, E., Wolozin, B. L., Riederer, P., & Murphy, D. L. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00147-u · Cited by 122
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Sorting receptor SORLA – a trafficking path to avoid Alzheimer disease
Willnow, T. E., & Andersen, O. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.125393 · Cited by 121
Alzheimer's Disease and the Amyloid β-Protein
Walsh, D. M., & Teplow, D. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00012-6 · Cited by 121
Bezzina, C., Verret, L., Juan, C., Remaud, J., Halley, H., Rampon, C., & Dahan, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119910 · Cited by 121
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 122
Lleó, A., Blesa, R., Queralt, R., Ezquerra, M., Molinuevo, J. L., Peña‐Casanova, J., Rojo, A., & Oliva, R. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1759 · Cited by 121
Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivo
Klyubin, I. V., Walsh, D. M., Cullen, W. K., Fadeeva, J. V., Anwyl, R., Selkoe, D. J., & Rowan, M. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03389.x · Cited by 121
(2008) · doi:10.1074/jbc.m801487200 · Cited by 105
Sato, N., Imaizumi, K., Manabe, T., Taniguchi, M., Hitomi, J., Katayama, T., Yoneda, T., Morihara, T., Yasuda, Y., Takagi, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006886200 · Cited by 121
Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years
Mondadori, C. R. A., Buchmann, A., Mustovic, H., Schmidt, C. F., Boesiger, P., Nitsch, R. M., Höck, C., Streffer, J. R., & Henke, K. (2006) · Brain · doi:10.1093/brain/awl266 · Cited by 121
Identification of Candidate Proteins Binding to Prion Protein
Yehiely, F., Bamborough, P., Costa, M. D., Perry, B. J., Thinakaran, G., Cohen, F. E., Carlson, G. A., & Prusiner, S. B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0130 · Cited by 121
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Reitz, C., Tokuhiro, S., Clark, L. N., Conrad, C., Vonsattel, J., Hazrati, L., Palotás, A., Lantigua, R., Medrano, M. A., Jiménez‐Velázquez, I. Z., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22308 · Cited by 120
Self-citationRoberts, S. B., Ripellino, J. A., Ingalls, K. M., Robakis, N. K. R. K., & Felsenstein, K. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42055-2 · Cited by 120
New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau
Yanker, B. A. (1996) · Nature Medicine · doi:10.1038/nm0896-850 · Cited by 120
Haplotypes extending across ACE are associated with Alzheimer's disease
Kehoe, P. G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg094 · Cited by 120
Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity.
Rabizadeh, S., Bitler, C. M., Butcher, L. L., & Bredesen, D. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10703 · Cited by 120
Masliah, E., Westland, C., Rockenstein, E. M., Abraham, C. R., Mallory, M. E., Veinberg, I., Sheldon, E., & Mucke, L. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00553-2 · Cited by 119
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118
Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease
Adwan, L. I., & Zawia, N. H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.010 · Cited by 118
Cellular Regulation of Amyloid Formation in Aging and Disease
Stroo, E., Koopman, M., Nollen, E. A. A., & Mata‐Cabana, A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00064 · Cited by 119
Genetics of neurodegenerative diseases: an overview
Pihlstrøm, L., Wiethoff, S., & Houlden, H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00022-5 · Cited by 120
Interleukin-1 and the Immunogenetics of Alzheimer Disease
Mrak, R. E., & Griffin, W. S. T. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.471 · Cited by 118
Alzheimer's disease: β‐Amyloid protein and tau
Morishima‐Kawashima, M., & Ihara, Y. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10355 · Cited by 118
β-Amyloid Modulation of Synaptic Transmission and Plasticity
Venkitaramani, D. V., Chin, J., Netzer, W. J., Gouras, G. K., Lesné, S., Malinow, R., & Lombroso, P. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3478-07.2007 · Cited by 118
Grice, D. E., Leckman, J. F., Pauls, D. L., Kurlan, R., Kídd, K. K., PAKSTIS, A. J., Chang, F. M., Buxbaum, J. D., Cohen, D. J., & Gelernter, J. E. (1996) · PubMed Central · Cited by 118
Knops, J., Suomensaari, S., Lee, M., McConlogue, L., Seubert, P. A., & Sinha, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2419 · Cited by 118
Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 117
The Pathogenesis of Alzheimer′s Disease: A Reevaluation of the “Amyloid Cascade Hypothesis”
Armstrong, R. A. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/630865 · Cited by 117
Gray, C. W., & Patel, A. J. (1993) · Molecular Brain Research · doi:10.1016/0169-328x(93)90037-p · Cited by 117
Mark, R. J., Ashford, J. W., Goodman, Y., & Mattson, M. P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(94)00150-2 · Cited by 117
Bressler, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.10.1589 · Cited by 117
Familial Alzheimer’s disease mutations in PSEN1 lead to premature human stem cell neurogenesis
Arber, C., Lovejoy, C., Harris, L., Willumsen, N., Alatza, A., Casey, J. M., Lines, G., Kerins, C., Mueller, A. K., Zetterberg, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108615 · Cited by 116
Self-citationAlzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Michalska, P., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080740 · Cited by 119
Díaz, J. C., Šimáková, O., Jacobson, K. A., Arispe, N. J., & Pollard, H. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813355106 · Cited by 116
Synaptic Dysfunction in Alzheimer’s Disease
Marcello, E. E., Epis, R., Saraceno, C., & Luca, M. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_25 · Cited by 115
Synaptic Elimination in Neurological Disorders
Cardozo, P. L., de Lima, I. B. Q., Maciel, E. M. A., Silva, N. C., Dobránsky, T., & Ribeiro, F. M. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603170511 · Cited by 115
Fatty acids, lipid metabolism and Alzheimer pathology
Hooijmans, C. R., & Kiliaan, A. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.081 · Cited by 115
γ-Secretase Substrate Concentration Modulates the Aβ42/Aβ40 Ratio
Yin, Y. I., Bassit, B., Zhu, L., Yang, X., Wang, C., & Li, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704601200 · Cited by 115
Ma, Q., Teter, B., Ubeda, O. J., Morihara, T., Dhoot, D. S., Nyby, M. D., Tuck, M. L., Frautschy, S. A., & Cole, G. M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3593-07.2007 · Cited by 115
Aggregation and disaggregation of senile plaques in Alzheimer disease
Cruz, L., Urbanc, B., Buldyrev, S. V., Christie, R. H., Gómez‐Isla, T., Havlin, S., McNamara, M. J., Stanley, E., & Hyman, B. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7612 · Cited by 115
Cras, P. P., van Harskamp, F., Hendriks, L., Ceuterick, C., van Duijn, C. M., STEFANKO, S. Z., Albert Hofman, D., Kros, J. M., Broeckhoven, C. V., Martin, J., et al. (1998) · Acta Neuropathologica · doi:10.1007/s004010050892 · Cited by 115
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass
Bonda, D., Wang, X., Lee, H., Smith, M. A., Perry, G. L., & Zhu, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1424-x · Cited by 114
Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
Mango, D., Saidi, A., Cisale, G. Y., Feligioni, M., Corbo, M., & Nisticò, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00778 · Cited by 114
Apolipoprotein E, Amyloid, and Alzheimer Disease
Bales, K. R. (2002) · Molecular Interventions · doi:10.1124/mi.2.6.363 · Cited by 114
Scott, W. K., Grubber, J. M., Conneally, P. M., Small, G. W., Hulette, C. M., Rosenberg, C. K., Saunders, A. M., Roses, A. D., Haines, J. L., & Pericak‐Vance, M. A. (2000) · The American Journal of Human Genetics · doi:10.1086/302828 · Cited by 114
Self-citationThe brain RAS and Alzheimer's disease
Wright, J. W., & Harding, J. W. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.012 · Cited by 113
The genetics of neuropsychiatric disorders
Bray, N. J., & O’Donovan, M. C. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818799271 · Cited by 113
Humanising the mouse genome piece by piece
Zhu, F., Nair, R., Fisher, E., & Cunningham, T. J. (2019) · Nature Communications · doi:10.1038/s41467-019-09716-7 · Cited by 114
Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics
Blue, E., Horimoto, A. R. V. R., Mukherjee, S., Wijsman, E. M., & Thornton, T. A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.016 · Cited by 113
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits
de Barreda, E. G., Pérez, M., Gómez‐Ramos, P., de Cristóbal, J., Martín-Maestro, P., Morán, A., Dawson, H. N., Vitek, M. P., Lucas, J. J., Hernández, F., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.017 · Cited by 113
Murray, K. D., Gall, C. M., Jones, E. G., & Isackson, P. J. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90202-x · Cited by 113
Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait‐linked phenotype.
Yamatsuji, T., Okamoto, T., Takeda, S., Murayama, Y., Tanaka, N., & Nishimoto, I. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00382.x · Cited by 113
Genetics of Alzheimer disease in the pre- and post-GWAS era
Ertekin‐Taner, N. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt26 · Cited by 112
Alzheimer's disease in the omics era
Sancesario, G. M., & Bernardini, S. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.06.011 · Cited by 113
Hereditary Amyloid Cardiomyopathy Caused by a Variant Apolipoprotein A1
Asl, K. H., Liepnieks, J. J., Asl, K. H., Uemichi, T., Moulin, G., Desjoyaux, E., LOIRE, R., Delpech, M., Grateau, G., & Benson, M. D. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65268-6 · Cited by 112
Cortical event-related potentials in preclinical familial Alzheimer disease
Golob, E. J., Ringman, J. M., Irimajiri, R., Bright, S., Schaffer, B., Medina, L. D., & Starr, A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1de77 · Cited by 112
Tan, L., Schedl, P. D., Song, H., Garza, D., & Konsolaki, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003966 · Cited by 112
Diagnóstico diferencial das demências
Neto, J. G., Tamelini, M. G., & Forlenza, O. V. (2005) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832005000300004 · Cited by 112
The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease
Campion, D., Martin, C., Heilig, R., Charbonnier, F., Moreau, V., Flaman, J., Petit, J., Hannequin, D., Brice, A., & Frébourg, T. (1995) · Genomics · doi:10.1016/0888-7543(95)80208-4 · Cited by 112
Protein Phosphatases and Alzheimer's Disease
Braithwaite, S. P., Stock, J. B., Lombroso, P. J., & Nairn, A. C. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00012-2 · Cited by 111
The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease
Sampietro, M., Caputo, L., Casatta, A., Meregalli, M., Pellagatti, A., Tagliabue, J., Annoni, G., & Vergani, C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00219-6 · Cited by 111
Mrak, R. E., & Griffin, W. S. T. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.7.679 · Cited by 111
Baulac, S., LaVoie, M. J., Kimberly, W. T., Strahle, J. M., Wolfe, M. S., Selkoe, D. J., & Xia, W. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00123-2 · Cited by 111
A critical analysis of the ‘amyloid cascade hypothesis’
A. Armstrong, R. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45562 · Cited by 110
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Rukhsana Sultana, A., & Butterfield, D. A. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9241-7 · Cited by 110
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Management of Alzheimer's Disease
Grossberg, G. T., & Desai, A. K. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m331 · Cited by 110
Altered Calcium Signaling and Neuronal Injury: Stroke and Alzheimer's Disease as Examplesa
Mattson, M. P., Rydel, R. E., Lieberburg, I. M., & Smith‐Swintosky, V. L. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb18285.x · Cited by 110
Bateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109
Steinbrecher, T. B., Zhu, C., Wang, L., Abel, R., Negron, C., Pearlman, D. A., Feyfant, E., Duan, J., & Sherman, W. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.007 · Cited by 109
Pharmacogenomics in Alzheimer's Disease
Cacabelos, R. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-205-2_10 · Cited by 109
Roses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 109
Self-citationUp-Regulation of Calcineurin Aβ mRNA in the Alzheimer's Disease Brain: Assessment by cDNA Microarray
Hata, R., Masumura, M., Akatsu, H., Li, F., Fujita, H., Nagai, Y., Yamamoto, T., Okada, H., Kosaka, K., Sakanaka, M., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4968 · Cited by 109
Murtomäki, S., Risteli, J., Risteli, L., Koivisto, U., Johansson, S., & Liesi, P. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490320216 · Cited by 109
Preimplantation Diagnosis for Early-Onset Alzheimer Disease Caused by V717L Mutation
Verlinsky, Y. (2002) · JAMA · doi:10.1001/jama.287.8.1018 · Cited by 109
Deng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
Neuronal Structure is Altered by Amyloid Plaques
Spires‐Jones, T. L., & Hyman, B. T. (2004) · Reviews in the Neurosciences · doi:10.1515/revneuro.2004.15.4.267 · Cited by 108
Cahill, C. M., Lahiri, D. K., Huang, X., & Rogers, J. T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.12.001 · Cited by 108
Fukumoto, H., Asami-Odaka, A., Suzuki, N., Shimada, H., Ihara, Y., & Iwatsubo, T. (1996) · Europe PMC (PubMed Central) · Cited by 108
Adam, S., Wiggins, S., Whyte, P., Bloch, M., Shokeir, M. H. K., Soltan, H. C., Meschino, W. S., Summers, A. M., Suchowersky, O., & Welch, J. P. (1993) · Journal of Medical Genetics · doi:10.1136/jmg.30.7.549 · Cited by 108
Genes, models and Alzheimer's disease
Chapman, P. F., Falinska, A. M., Knevett, S. G., & Ramsay, M. F. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02285-5 · Cited by 108
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides
Ma, J., Brewer, H. B., & Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00112-1 · Cited by 108
Guerreiro, R. J., Lohmann, E., Kinsella, E., Brás, J. M., Luu, N., Gurunlian, N., Dursun, B., Bilgic, B., Santana, I., Hanagasi, H., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.009 · Cited by 107
Mechanisms of neuronal death in disease: defining the models and the players
Ribé, E. M., Serrano‐Saiz, E., Akpan, N., & Troy, C. M. (2008) · Biochemical Journal · doi:10.1042/bj20081118 · Cited by 107
Hori, Y., Hashimoto, T., Wakutani, Y., Urakami, K., Nakashima, K., Condron, M. M., Tsubuki, S., Saido, T. C., Teplow, D. B., & Iwatsubo, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608220200 · Cited by 107
Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism
Tanaka, M., Bohár, Z., & Vécsei, L. (2020) · Molecules · doi:10.3390/molecules25030564 · Cited by 107
Metadata
- Authors
- Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M., & Hardy, J.
- Affiliations
- St Mary's Hospital (GB)
- Yale University (US)
- University of Wales (GB)
- Duke Medical Center (US)
- Venue
- Nature
- Published
- 1991-02-21
- Volume
- 349
- Issue
- 6311
- Pages
- 704-706
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058723245
- Cited by
- 4,659
- References
- 30
- Citations by year
- 2026: 62 · 2025: 85 · 2024: 111 · 2023: 88 · 2022: 112 · 2021: 130 · 2020: 149 · 2019: 115 · 2018: 112 · 2017: 130 · 2016: 160 · 2015: 131 · 2014: 129 · 2013: 166 · 2012: 135
- FWCI
- 153.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute on Aging (AG05 128, P50AG005128)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- familial Alzheimer's disease, amyloid precursor protein gene, APP gene mutations, missense mutations, genetic heterogeneity, co-segregation, early-onset Alzheimer's disease, late-onset Alzheimer's disease, beta-amyloid peptide
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 21, Exons, Genetic Testing, Genotype, Humans, Genetic Linkage, Molecular Sequence Data, Mutation, Pedigree, Protein Precursors, Polymorphism, Restriction Fragment Length, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
